8/2/2019 3rd Sem Report
1/44
AGLOBAL / COUNTRY STUDY AND REPORT
ON
Companies of Switzerland
Submitted toPARUL INSTITUTE OF MANAGEMENT
IN PARTIAL FULFILLMENT OF THEREQUIREMENT OF THE AWARD FOR THE DEGREE OF
MASTER OF BUSINESS ASMINISTRATION
In
Gujarat Technological University
UNDER THE GUIDANCE OFProf. Kinjal Palvankar
(I/c director)
Submitted by(STUDENT NAME)
[Batch : 2010-12, Enrollment No.:____]MBA SEMESTER III/IV
PARUL INSTITUTE OF MANAGEMENTMBA PROGRAMME
Affiliated to Gujarat Technological UniversityAhmedabad
8/2/2019 3rd Sem Report
2/44
8/2/2019 3rd Sem Report
3/44
PREFACE
PARUL INSTTUTE OF MANAGEMENT
As a part of curriculum in 3rd semester the student have to do a research on the country
report, in the subject Global Country Report (GCR). This helps us to study what are the
current opportunities are going on in the country (Switzerland).
Our group topic title is company Analysis of Switzerland.
The objective of this report is to explore opportunities in companies of Switzerland
The guide for our research is Mrs.Kinjal Palvankar, director in charge of Parul Instituteof Management (MBA).
Group members
Pranav Darji (32)
Khimaji Chauhan (33)
Chaitnay Panchal (34)
Ravi Desai(35)
Modh Pratik(36)
Jasmit Jadav(37)
8/2/2019 3rd Sem Report
4/44
Index
SR no topoic Pageno
1 Inroduction2 UBS3 Novartis
4 Conclusion5 4th sem
8/2/2019 3rd Sem Report
5/44
Introduction
Sitzerland is on top position in worlds largest private banking center with about
510 big banking institution. It is expected that approximately 35% of all private wealth
globally is held in switzerland. Current years have seen the switzerland banking sector
services market goes to sophesticated services for competitive price for major
professional clients. This marked change to the traditional minor sized private accounts
is the result of new lagislative nad market forces joint.
So banking sector is very fast growing in the switzerland.
There is pharmaceutical sector in switzerland also is very big and developing
indusrty. The share of pharma industry in GDP is about 5.7% in the economy.
8/2/2019 3rd Sem Report
6/44
Top ten companies in Switezerland
1. Novartis AG Sector: Health Care
2. Nestle S.A. Sector: Consumer Goods
3. Roche Holding AG Sector: Health Care
4. ABB Ltd Sector: Industrials
5. Credit Suisse Group Sector: Financials
6. UBS AG Sector: Financials
7. Zurich Financial Services AG Sector: Financials
8. Syngenta AG Sector: Basic Materials
9. Compagnie Financiere Richemont S.A. Sector: Consumer Goods
10. Holcim Ltd Sector: Industrials
8/2/2019 3rd Sem Report
7/44
UBS (United Bank of Switzerland)
UBS AG is a Swiss global financial services company headquartered in Basel
and Zrich, Switzerland. This provide services in investment banking, Asset Wealth
management services to the private, corporate and the institutional client worldwide and
retail clients in Switzerland. It was working in more than 40 countris and it was
considere as the world's second major company of private wealth assets, with over CHF
2.2 trillion in invested assets. UBS operates in majorly in the financial centers worldwide
with the help of 50 countries office and 64,000 employees around the world wide. UBS
was originally an abbreviation by the Union Bank of Switzerland, however, its ceased to
be consider after its 1998 merger with Swiss Bank Corporation.
UBS is working over 150-year heritage to serve to the private, institutional and
corporate customer in the world, as well as retail customer in the Switzerland.
Headquartere in Zurich and Basel, Switzerland, UBS has offices in more than 50
countries, with all major fiscal center, and employ about 65,000 inhabitants. In Swiss
company law, UBS is organized as an Aktiengesellschaft, a business that has issued
shares of common stock to investors. UBS AG is the parent company of the UBS
Group.
The operational formation of the Group comprises the business hub and four
company division: Wealth Management in Swiss Bank and also in Wealth Management
America and also in Global Asset Management and and also in the Investment Bank.
8/2/2019 3rd Sem Report
8/44
Company overview
History
UBS AG was established from the 1998 by the merger of Swiss Bank
Corporation to the Union Bank of Switzerland. And UBS get a position as the second
biggest bank in Europe and 10th major financial institution in the world. UBS has 4 main
units. UBS Wealth Management and Business Banking includes the leading retail
banking operation in Switzerland, with 540 branches and 2200 ATMs helping about 4
million persons and corporate customers, beside with the world's top private banking
business, with the latter offer wealthy customers a large range of separately planned
products and services.. UBS Warburg operates worldwide as the group's investment
banking and securities business. UBS PaineWebber is one of the top assets
management firms in the United States, UBS have network in more than 8,500 financialadvisors managing $436 billion of invested assets worldwide.
The 1998 combination of SBC and Union Bank of Switzerland into the firm weknow today created a leading global wealth manager and improved the new firmsprospects of becoming a global bulge-bracket investment bank and a leading globalinstitutional asset manager.
8/2/2019 3rd Sem Report
9/44
Type Aktiengesellschaft (AG)
Public company
Business sector Financial Industry
Founded in 1854
Headquarters Zurich & Basel, Switzerland
Operating in 52 countries
Employees 64,617
Vision
We are determined to be the best global financial services company. We focuson wealth and asset management, and on investment banking and securitiesbusinesses. We continually earn respect and trust from clients, shareholders and staffthrough our ability to anticipate, learn and shape our future. We share a commonobjective to succeed by deliver excellence in what we do.
Mission
The UBS mission is to have a client-focused approach, creating customizedfinancial solutions based on their global resources and capabilities.
Value
Our clients success is our success. We take the time to understand theirobjectives and commit our resources to develop effective solutions, helping them meetor exceed their goals.
8/2/2019 3rd Sem Report
10/44
Integrated Business Model
We are one firm. Our business is designed to put clients at the center of ourthinking and deliver the entire firm to meet or exceed their needs. We share commonaspirations, common values, and a common corporate identity. We work together
across organizational boundaries to achieve common goals and co-operate indeveloping new products and services. We do, however, operate in different businessactivities, each with a specific set of standards of excellence. We integrate, not for itsown sake, but to create valueand securities businesses and our bank in Switzerlandhave distinct processes, organizations and cultures. They compare themselves with thebest in their fields and are each accountable for their own success. Balancingintegration opportunities and the need for business distinctiveness in such a large,diverse company is a continual challenge. Mastering this is a major source ofcompetitive advantage and will be commensurately rewarded. It is, therefore, a vitalleadership task for our senior management that requires sustained good business
judgment. A strong professional network among our senior management is key to
successfully executing this task.
Ethical belief
Integrity and Privacy: UBS expect our people to behavior themselves in a manner thatis above reproach. Our integrity is key to preserving our most precious asset ourstatus. We respect our clients right to confidentiality and use information with suitablecarefulness.
Corporate Responsibility: UBS is a member of the worldwide society and perform asa liable corporate inhabitant. We, both as a corporation and through our people, strive to
contribute absolutely and actively to the community where we do business.
Culture
UBS's inclusive culture encourages partnership and supports our employees'professional and personal ambitions. Open-mindedness, teamwork, honesty andrespect are the cornerstones of how we work together. It is through this collaboration ofdifferences that we are able to help individuals -both our employees and clients become
more successful.
8/2/2019 3rd Sem Report
11/44
Focus area
The excellence,inspiration and commitment of our employees is critical tomeeting clients needs and executing our business strategy. This is reflected in theinvestment we make on the basis of managing talent, and in the development of our
performance culture and our leadership.
Financial Target
We seek to deliver returns for our shareholders through achieving sustainable,profitable growth across all of our businesses. We assume risks and manage themprudently in the interest of all our stakeholders. Being dedicated to shareholder valuecreation, within defined risk parameters, also means creating value for all stakeholders.
Our strategic focus on growth businesses, our scale and operating leverage, andour efficient capital management support our financial targets of a double digit annualEPS growth and an after tax return on equity above 20% across periods of varyingmarket conditions.
Through revenue growth and disciplined cost management, we will achieve cost /income ratios of our businesses at levels that are in line with respective best-in-classcompetitors. A key measure of success is to what extent current and new clients acrossall our wealth and asset management businesses are entrusting their assets to us. Netnew money is, therefore, a key indicator of the execution of our growth strategies. Weseek to achieve a superior market value corresponding to our true performance andpotential by communicating transparently, openly and consistently with our investorsand with the financial markets.
8/2/2019 3rd Sem Report
12/44
Performance of the company
In 2010, UBS has generated a net profit attributable to UBS shareholders of CHF7.5 billion, a significant improvement over the net loss of CHF 2.7 billion in 2009. Thisincrease was primarily due to a significant improvement in fixed income, currencies and
commodities revenues from a loss in 2009. In addition, a reduction in credit lossexpense, as well as significantly lower own credit losses on financial liabilitiesdesignated at fair value supported the result. Operating expenses were slightly lowerthan in 2009, when we recorded higher restructuring costs and a goodwill impairmentcharge related to the sale of UBS Pactual. Further, UBS had reduced fixed costsexcluding bonus and significant non-recurring items to CHF 19.9 billion in 2010, in linewith our communicated target of below CHF 20 billion, despite increased costs forlitigation provisions compared with 2009. Diluted earnings per share were CHF 1.96 in2010, compared with negative CHF 0.75 in 2009.
8/2/2019 3rd Sem Report
13/44
NOVARTIS
History
Novartis was formed in 1996 through merger of ciba-geigy and sandoz, two
companies with rich and diverse corporate history. Through the years, Novartis and
forerunner companies have discovered and developed many innovative products for
patients and consumers worldwide.
Novartis Focused solely on healthcare, Novartis offers a diversified portfolio to
best meet these needs, innovative medicines, its provides eyes care products, cost-
saving generic pharmaceuticals products, consumer health products, preventive
vaccines and diagnostic tools. Novartis is the only company with leading positions in
each of these areas.
An uncertain economy and regulatory reform continue to create downwardpressure on the healthcare industry. As healthcare spending outpaces economicgrowth, healthcare budget in many countries will be impacted, resulting in increasepricing pressures.
Novartis is adapting to these changes by shifting from transactional approach toa more integrated approach, where we work together with physicians and customers toenable better patient outcomes. Novartis is working closely with hospitals, physiciansand initiating pilot programs how to best meet changing customer expectation.
Novartis International AG is a multinational pharmaceutical company based in
Basel, Switzerland, ranking number three in sales among the world-wide industry.
Company sales totalled 36.173 billon US$ in 2008. Currently,Novartis is the sixth
largest pharmaceutical company in terms of revenue with a profit margin of about 20%.
Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a
large manufacturer of generic drugs.
Novartis is a full member of the European Federation of Pharmaceutical
Industries and Associations (EFPIA) and of the International Federation ofPharmaceutical Manufacturers and Associations (IFPMA)
8/2/2019 3rd Sem Report
14/44
General overview
Type Public company
Business sector pharmaceutical Industry
Founded in 1996
Headquarters Basel, Switzerland
Operating in world wide
Employees 1,23,886
Products pharmaceutical
Generic drugs
Over-the-counter drugs
Vaccines
Animal health
Diagnostics
Mission
We want to discover, develop and successfully market innovative products toprevent and cure diseases, to ease suffering and to enhance the quality of life. We alsowant to provide a shareholder return that reflects outstanding performance and toadequately reward those who invest ideas and work in our company.
8/2/2019 3rd Sem Report
15/44
NOVARTIS STRATEGIES FOR SUSTAINABLE GROWTH
The cornerstone of Novartis strategy is our diversified healthcare portfolio acrosshigh-growth segments of the healthcare industry and geographies. Novartis is the onlyhealthcare company with leading positions in pharmaceuticals, eye care, generics,
vaccines and diagnostics, over-the-counter medicines and animal health. We believethat the diversity of our business and product portfolio allows us to capture opportunitiesacross the global healthcare market, while balancing our risk and exposure tomacroeconomic effects. We expect our broad portfolio will help us maintain growthdespite the loss of revenues due to patent expiration.
One of the top companies
Novartis is Switzerlands largest healthcare company. The Novartis Groupreported worldwide sales of about CHF 52 billion. Novartis ranked as one of the top 30
companies worldwide in terms of market value. In the IMS-PADDS ranking, Novartis isone of the largest companies in global pharmaceutical sales.
Top ten global pharmaceutical companies
Companies Country USD billion Growth vs. 2010(%)
Pfizer USA 50.2 0.1Novartis Switzerland 45.7 11.0Merck & Co USA 35.5 7.0Sanofi-aventis France 34.7 2.5
AstraZeneca UK 32.8 3.2Roche Switzerland 30.4 5.9GlaxoSmithKline UK 30.1 1.5Johnson & Johnson USA 24.5 0.8Abbott USA 22.6 6.5Lilly USA 21.3 8.5Source: IMS PADDS Monthly, 59 countries, Now 2011
8/2/2019 3rd Sem Report
16/44
Employment
Novartis currently employs 123,686 people worldwide. Of these, 13,548 work inSwitzerland spread over twelve sites: Basel BS/BL, Bern BE, Cham ZG, Fribourg FR,Geneva GE, Hnenberg ZG, Locarno TI, Nyon VD, Schaffhausen SH, Schlieren ZH, St-
Aubin FR und Stein AG. The most important of these are the two Basel cantons, whereNovartis is the largest private employer in the region and provides jobs for numerouscross-border commuters. Nearly 14 % of Basel-based Novartis associates live inGermany, while 20 % reside in France.
One of the most innovative companies
Novartis concentrates on the development of innovative medicines and isconstantly stepping up efforts to make new forms of treatment available to patients.
Scientists cover a broad spectrum of disciplines and lead the industry with skills
that range from transplantation and immune suppression to breakthroughs in oncologyand disease-modifying treatments forAlzheimers.
Pipeline contains more than 130 projects in various phases of development including potential new products and additional indications or new formulations forestablished products. In the next few years, we will launch a substantial number of newproducts on the market worldwide.
Largest research hub
Novartis global research organization, the Novartis Institutes for Bio-MedicalResearch (NIBR), is comprised of nine sites around the world. The largest site islocated in Basel, Switzerland.
The research hub of Switzerland is of central importance for Novartis researchand development. In 2011 we invested a total of CHF 3.3 billion in this country, worthover 39 % of our global R&D spending.
8/2/2019 3rd Sem Report
17/44
Performance
Net sales rise 14% (+14% in constant currencies) to USD 50.6 billion driven bystrong growth in all businesses, including USD 2.4 billion from consolidation of Alcon.Operating income advances 15% to USD 11.5 billion on business expansion and
productivity improvements. Core operating income rises 22% to USD 14.0 billion. Netincome up 18% and core net income up 17% to USD 10.0 billion and USD 12.0 billion,respectively.
8/2/2019 3rd Sem Report
18/44
CONCLUSION
As we have studied about the companies of Switzerland. The growth of the
companies is increasing. We have studied about the two companies that are
NOVARTIS and UBS. These two companies are well reputed in Switzerland.
Opportunities in Switzerland of these two companies are better for business
purpose as well as job purpose. As we found from this study the financial sector in
Switzerland is one of the strong sector.
The pharmaceutical sector is also growing rapidly in Switzerland.
8/2/2019 3rd Sem Report
19/44
4th sem
IndexSR no Topic Page no
1 Nycomed2 Novartis3 Alliance Boots4 Roche5 Sandoz6 Summery
8/2/2019 3rd Sem Report
20/44
NYCOMED PHARMACEUTICALS
VISSION
Nycomed vision is to strive for superiority in all we do to develop the quality of life for
patients about the worldwide.
MISSION
Nycomed mission is to bring medicines that matter to patients and healthcare providers.
GENERAL OVERVIEW
Nycomed is European Based Pharmaceutical Company. Nycomed Is Privately owned
primarily By The Two Private Equity Investors Named Nordic Capital And CSFB
Alternative Capital. Production Is Located In Main Following Countries.
1. Norway
2. Denmark
3. Poland
4. Austria
5. Belgium
6. Germany
7. Estonia
8. India
9. Mexico
10. Brazil
11. Argentina
Head Office Is Located In Zurich, Switzerland.
Nycomed Is 28th Largest Pharmaceutical Company In all over world
In more than 70 Countries, where nycomed subsidiaries are present.
http://en.wikipedia.org/wiki/Denmarkhttp://en.wikipedia.org/wiki/Polandhttp://en.wikipedia.org/wiki/Austriahttp://en.wikipedia.org/wiki/Belgiumhttp://en.wikipedia.org/wiki/Germanyhttp://en.wikipedia.org/wiki/Estoniahttp://en.wikipedia.org/wiki/Indiahttp://en.wikipedia.org/wiki/Mexicohttp://en.wikipedia.org/wiki/Mexicohttp://en.wikipedia.org/wiki/Indiahttp://en.wikipedia.org/wiki/Estoniahttp://en.wikipedia.org/wiki/Germanyhttp://en.wikipedia.org/wiki/Belgiumhttp://en.wikipedia.org/wiki/Austriahttp://en.wikipedia.org/wiki/Polandhttp://en.wikipedia.org/wiki/Denmark8/2/2019 3rd Sem Report
21/44
MAIN PRODUCT OF NYCOMED
Gastroenterology
Nycomeds biggest-selling product, pantoprazole (acid-related Gastroenterology
disorders)
Specialty products
Products primarily for specialist doctors, including Instanyl ( cancer pain),Calcium D3,
TachoSil (surgical patch) and Preotact (osteoporosis)
Respiratory
Products for respiratory and related conditions, such as Alvesco (asthma), Omnaris(allergic rhinitis) and recently launched Daxas (COPD)
OTC
Broad portfolio of over-the-counter products marketed in Europe and emerging markets
Regional and local Rx
Portfolios adapted to local needs, primarily composed of branded generics
Nycomed US
Dermatology products for the US market
8/2/2019 3rd Sem Report
22/44
BUSINESS PARTNER
In september 2010 nycomed acquire 51.34% stake in GUNGDONG TECHPOL BIO-
PHARMA a very fast growing pharmaceutical market in CHINA
In september 2010 nycomed new therapy for chronic obstructive pulmonary dieses
called DAXAS was approved in the EU and CANADA. It Launched In GERMANY,
DENMARK, UNITED KINGDOM, ROMANIA, NORWAY.
Nycomed entered into an agreement in 2010 with MERSK&CO. one of the largest
pharmaceuticals companies to co promote DAXAS.
In april 2010 Nycomed launched TECHOSIL for SURGICAL PATCH with US partner
BAXTER INTERNATIONAL.
Nycomed formed collaboration with RUSSIAN BASED GE HEALTHCARE for build their
strength to sell diagnostic contrast agent in dynamic market.
The joint venture with ZYDUS began production of active pharmaceutical ingredients in
MUMBAI, INDIA in 2010.
FINANCIAL DATA
1) TURNOVER BY PRODUCT IN 2009-2010
0
200
400
600
800
1000
1200
1400
Turnover 2010
Turnover 2009
8/2/2019 3rd Sem Report
23/44
ANALYSIS:- Here we considered Turnover of NYCOMED on the bases of their product
in 2009-2010. Nycomed mainly focused in gastroenterology product. So here turnover
of gastroenterology is higher than other product it contribute almost 1000 Thousandturnover.
2) SHAREHOLDER PATTERN IN 2009-2010
ANALYSIS:- As debt capital is cheap sources to raise fund from market so, NYCOMEDused debt sources higher than equity sources. NYCOMED sharecapital pattern of debt
compare to 2009 to 2010 it decrease 37,00,000 Thousand approxe to 36,00,000
Thousand approxe. while Equity compare to 2009 to 2010 it decrease 1,50,000
Thousand approxe to 1,40,800 Thousand approxe.
0
500,000
1,000,0001,500,000
2,000,000
2,500,000
3,000,000
3,500,000
4,000,000
Net debt Equity Net turnover
Shareholder Pattern Year
2010 Thousand
Shareholder Pattern Year2009 Thousand
8/2/2019 3rd Sem Report
24/44
3) NET TURNOVER BY REGION
ANALYSIS:-
Contribution of turnover of NYCOMED by region is more in European countries
i.e.43%.while Asian-Pacific and African Countries Contributes 8% Turnover.
Europe
43%
North
America
13%
Russia / CIS
15%
Latin America
12%
Asia-Pacific, Africa
and Middle East
8%
Contract
Manufacturing3%
Out-licensing
6%
NET TURNOVER BY REGION
8/2/2019 3rd Sem Report
25/44
NOVARTIS
History
Novartis was formed in 1996 through merger of ciba-geigy and sandoz, twocompanies with rich and diverse corporate history. Through the years, Novartis and
forerunner companies have discovered and developed many innovative products for
patients and consumers worldwide.
Novartis provide healthcare solution that address the developing need of patients
and society. Focused solely on healthcare, Novartis offer a diversify portfolio to top
meet these needs, pioneering medicines, eyes care products, cost-saving general
pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools.
Novartis is the single company with top positions in each of these areas.
General info
Foundation - Ciba-Geigy and Sandoz merged in 1996 to form Novartis
Headquarters- Basel, Switzerland
Product- More than 130 projects at various pipeline stages of development
Locations- Novartis is represented by affiliated worldwide companies in over140 countries
Locations- Basel BS/BL, Bern BE, Cham ZG, Switzerland Fribourg FR, Genf
GE, Hnenberg ZG Locarno TI, Nyon VD, Schaffhausen SH,
Schlieren ZH, St-Aubin FR, Stein AG
Business Pharmaceuticals
Divisions Alcon
Sandoz
Consumer Health, Vaccines and Diagnostics
8/2/2019 3rd Sem Report
26/44
NOVARTIS STRATEGIES FOR SUSTAINABLE GROWTH
The cornerstone of Novartis strategy is our diversified healthcare portfolio across
high-growth segments of the healthcare industry and geographies. Novartis is the single
healthcare company with top position in pharmaceuticals, eye care, generics, vaccines
and diagnostics, over-the-counter medicine and animal health. We believe that the
multiplicity of our business and product portfolio allow us to capture opportunity across
the global healthcare market, while balancing our risk and exposure to macroeconomic
effects. We expect our broad portfolio will help us continue growth in spite of the loss of
revenues due to patent termination.
OUR PRIORITIES: INNOVATION, GROWTH AND PRODUCTIVITY
Novartis is committed to becoming the most successful and valued healthcare
company in the world. To achieve this, we base our operations on three strategic
priorities: leading innovation through new research methods and new collaborations
with industry stakeholders to better address customer and patient needs; accelerating
growth by responding to key market opportunities and delivering new treatments quickly
and efficiently to customers and patients; and improving productivity by streamlining our
organization in order to improve profitability and free up resources for new research and
development investments. We believe that by focusing on these principles we can
enhance our capabilities in meeting the worlds healthcare needs and continue to drive
value for our shareholders.
8/2/2019 3rd Sem Report
27/44
Export Growth 1980 - 2010 (1980 = 100 %)
From 1980 to 2010 exports of pharmaceuticals, vitamins and diagnostics have rise from
100% to over 1540 %. In the other specialties areas the growth has been more modest
with increase from 130 % to 350 %. (Beginning with 1988 pharmaceutical and crop
protection intermediates are also included in the export figures, reducing the share of
organic products).
Net sales growth by segment
0 5 10 15 20
Group
consumer health
Sandoz
Alcon
pharmaceutical
constant currency
US dollars
8/2/2019 3rd Sem Report
28/44
Net sales growth by region
Leading export nation(bn EUR)
Switzerland has share of 4% in the world export of pharmaceutical products,
Switzerland is seventh biggest export nations in the world.
Switzerland is number 95 in terms of population and number 147 in terms of its area
extension. SConsidered on its gross domestic product index however, Switzerland
takes the position of number 33.
Novartis is one of Switzerlands largest exporters, accounting for 14.3 % of total
national net exports. In 2011 Swiss exports totalled CHF 197.6 billion, of which Novartis
accounted for CHF 28.3 billion. Total Swiss imports amounted to CHF 173.7 billion, of
which Novartis imports were CHF 14.2 billion (including intermediate products). In other
words, Novartis exports exceeded imports by CHF 14.1 billion.
0 10 20 30
Group
Canada and Latin
Asia/Africa/Australasia
Europe
United States
Constant Currency
US Dollars
8/2/2019 3rd Sem Report
29/44
Growth and stable anchor1
The pharmaceutical industry is a key sector of the Swiss economy and a major
employer. Including upstream and downstream sectors, over 130,000 jobs depend on
the pharmaceutical industry.
The pharmaceutical industry has above-average productivity. The sector is directly and
indirectly responsible for added value amounting to nearly CHF 30 billion,
corresponding to 5.7 percent of the nominal gross domestic product.
The pharmaceutical industry is Switzerlands most important export sector, accounting
for over 30 percent of total exports. Its exports rose from CHF 8 billion to over CHF 60
billion in 2010.
1Source: Interpharma/Polynomics 2011 Importance of the Pharmaceutical Industry for Switzerland
8/2/2019 3rd Sem Report
30/44
Alliance Boots GmbH
Alliance Boots GmbH is leading international, pharmacy health and beauty
group. It has two core business activities pharmacy health and beauty retailing, and
pharmaceutical wholesaling and distribution. It is presence in more than 25 countries. It
has revenue in excess of 23.3 billion. It was formed in 2006 by a merger of the listed
British high street pharmacist Boots Group and the pan-European wholesale and retail
pharmacy group Alliance UniChem. Alliance Boots was initially listed on the London
Stock Exchange. In 2007 they were bought out in a private equity transaction. In 2008
the trading business was transferred to a Swiss GmbH, it was a wholly owned
subsidiary of a British company, AB Acquisitions Holdings Limited, it was owned by the
private equity firm Kohlberg Kravis Roberts (KKR) and the Italian businessman StefanoPessina, he built Alliance UniChem and is today the executive chairman of Alliance
Boots
The Group's operations are mainly carried out under the Boots and Alliance Healthcare
brands. Boots UK is a UK's leading pharmacy-led health and beauty retailer. Alliance
Boots is also the largest pharmaceutical wholesaler in the UK by its Alliance Healthcare
(Distribution) Ltd business.
Alliance Boots employs have 115,500 staff and operates. It has more than 3,280 retail
stores, around 3,180 pharmacies. Alliance Boots' pharmaceutical wholesale division
serves over 160,000 pharmacies, doctors, hospitals and health centers with the help of
370 depots.
Mission
Its mission is to become the worlds leading pharmacy-led health and beauty group.They seek to develop their core businesses of pharmacy-led health and beauty retailing
and pharmaceutical wholesaling across the world and become a significant player in
many major international markets.
8/2/2019 3rd Sem Report
31/44
Purpose
There purpose is to deliver products and services that help people look and feel their
best.
Strategy
Its strategy is to focus on its two core business activities of pharmacy-led health and beauty
retailing and pharmaceutical wholesaling and distribution, while increasingly developing and
internationalizing its product brands to create a third dimension.
Objectives
Making Boots more convenient and accessible for its customers
Improving its customers in-store shopping experience
Continuing to provide a customers excellent value
Developing country specific Boots branded trading formats to meet local need
Increasingly differentiating its product offering
Creating a compelling multi-channel health and wellbeing consumer offering
Growth (Profit + 67% in the last four year)
Year 2006-07 2007-08 2008-09 2009-10 2010-11
profit 695 839 935 1052 1164
0
200
400
600
800
1000
1200
2006/07 2007/08 2008/09 2009/10 2010/11
Profit
Profit
8/2/2019 3rd Sem Report
32/44
Hoffmann La-Roche
Company Profile
Roche is Aktiengesellschaft type of company of switzaerland, it is founded in the
year 1896 and the founder of this company is Fritz Hoffmann-La Roche. Its
Headquarters is located at Basel; Roche has shares listed on the SIX Swiss Exchange.
Main Products of the roche is Switzerland Pharmaceuticals and Diagnostics its
includes Xenical, Valium, Dormicum, MabThera, Tarceva, Invirase Roaccutane,
Avastin, Accutane, Rohypnol, Herceptin, Valcyte, Boniva , Tamiflu, Zelboraf, Klonopin,
Xeloda, and Erivedge.
Roche have Revenue approx 42.531 billion CHF, Profit was 9.544 billion CHF at
2012 March, Their Total assets is 61.576 billion CHF and Number of employees are
working approx 81,000.
La Roche is a member of the European Federation of Pharmaceutical Industries
and Associations (EFPIA).
Management of the Company:
CEO - Severin Schwan
Chairman - Franz Humer
COO - Pascal Soriot
8/2/2019 3rd Sem Report
33/44
Time line of the Roche
Year Particulars1896 Founded1934 Become first company to Produce synthetic vitamin C
1956 Creation of the first anti-depressant1957 Introduced Tranquilizers1962 Produce various HIV tests and antiretroviral drugs1976 Accident at a chemical Factory1982 Acquired Biomedical Reference Laboratories for US$163.5 million1990 Become one of the largest clinical laboratories networks1992 Bought the patents for the polymerase chain reaction technique1994 Acquired syntax1995 Roche sold biomedical laboratories to national health laboratories2009 Roche agreed to acquired Genentech2009 Become wholly owned subsidiary group of company
2011 Company received the facility of the year award
Research and Development of the company
R&D programme is running in zurich Switzerland.
The company is also involved in the public research.
It does its work in research with the joint company to innovative work in medicine.
In 2011 financial position of the company
Pharma division-net operating assets
2011(in mchf) 2010(in mchf)receivable 7861 7966inventories 3177 3322payble 5593 5522net working capital 5445 5766
Property ,plant ,equipment 11586 12224goodwill 4851 4635provision 2124 2489Other long term assets 250 225Long term net operatingassets
14563 14595
Net operating assets 20008 20361
8/2/2019 3rd Sem Report
34/44
In the year of 2011 26 % net is increase. This is all about pharma as well as diagnosis.it
increase by only 7% by translated.global structure as well as amortization in intangiblr
asset.
Net income of roche
By thr solid performance of company we know that 26% of net income is increase.this is
all due to low financial constad and low tax by the government.and on core area net
income of the company was about 11%.
Income Tax by the company
And core tax of the company is decrease by about 0.6% to 21.3% in the year of
2011.this was low decrease in profit percentage drastically.and also tax rate is also
decrease by basel ,Switzerland government. And this was very helpful to company in to
profit of the company.
Share of the company
From the top most company list roche has ranked 6 among these all in the world. here
TSR =share price +dividend. And roche has number 6 in the exchange rate also. And at
the end of the year return was about 22% for the share of the company.
And common performance of share and nonvoting equity security was also about 22-23
% and over all return of both was about 16-17%.and flow was the rewarded by the
company is strong share .
Ethics of the company
In the ethics roche is generally used the integrity and courage passion. And the
companys employees complete their full practice as code of conduct and overall
performance of the company is flow the value of the company roche.
8/2/2019 3rd Sem Report
35/44
Alcon Pharmaceutical
Mission
To provide innovative products that enhance quality of life by helping people see better.
General Overview
Alcon was established in 1945. Alcon was the joint effort between pharmacists,RobertAlexander and William Conner, who established a small pharmacy in Fort Worth, Texas.They craete the name Alcon by combining the 1st syllable of their last name.
The strengths of Alcon is, CIBAVISION and Novartis Ophthalmics unit into one eye carebusiness with Alcon becoming the 2nd largest division of Novartis.With the help ofthese resources and scale, Alcon becomes the widest producer of eye care products insurgical, pharmaceutical and vision care products. They provide their products andservices in 180 markets and its operations done in 75 countries.
Present working countries of Alcon
1. European countries
2. Czech Republic
3. Ireland
4. Sweden
5. United Kingdom
6. Africa
7. Asian-pacific countries
Product detail of Alcon
It develop and manufacturing market surgical equipment and devices.And also
Pharmaceuticals,vision care services and products provided in more than 180countries market. The aim of Alcon's ability is to deliver "best in class" products and
services year after year is to research & development organization.
The main purpose of Alcons manpower including engineers, scientists and also
medical department are dedicated to meeting for the world eye health needs.In
8/2/2019 3rd Sem Report
36/44
2010,Alcon invested USD 747 million in the research on new products to enhance and
restore vision.
In the next five years, Alcon is ready to invest approx. USD 4 billion to discover and
ready to develop new ways to find solutions for vision conditions and eye diseases.
(1.) Surgical Instruments of Alcon
Alcon is the market leader in eye care surgical products,Alcon providing thecomprehensive surgical portfolio in the overall market.Eye care professional, patientsand also their families trust that alcon surgical instrument apply rigorous scientificresearch to develop for the solution of cataract, retinal and refractive surgerytechnologies.
(2.) Pharmaceutical Products of Alcon
Alcon maintain its position as the market leader in pharmaceuticals products for the eyeand ear and its continue to lead the way to advanced treatment for patients sufferingfrom eye allergies and glaucoma, eye allergies,eye and ear infections.Alcon offers onlyonce-daily prescription of eye drop and its approved by the FDA register for to thetreatment for allergic conjunctivitis, PATADAY ophthalmic solution, called PATANOLSophthalmic solution in the markets, and also the combination between antibiotic and
anti-inflammatory drug ready to treat ear infections, CIPRODEX Otic suspension.
8/2/2019 3rd Sem Report
37/44
(3.) Vision Care Product
Through the integration of CIBA VISION with Alcon, Alcon is now one of the largestmanufacturers of lens care and also contact lenses products.recently Alcon have threeleading brands of contact lenses from CIBAVISION named as Air Optix, Dailies andFreshLook.
FINANCIAL DATA
1) Earning Data
Analysis:-
From the above graph we can conclude that revenue of Alcon has increased in the year2010. It was nearer to 6500$ in the year 2009 and there is an increment of in the year2010. So it reaches to above 7000$ in the year 2010.
$-
$1,000.00
$2,000.00
$3,000.00
$4,000.00
$5,000.00
$6,000.00
$7,000.00
$8,000.00
Year 2010 Year 2009
Sales
Gross profit
8/2/2019 3rd Sem Report
38/44
2) Sales By Category
Analysis:-
From the above chart we can say that there is alaucoma and infection related productshaving higher sales. In sales 40% contribution gives glaucoma product in its totalrevenue while nearer to 25% contribution gives Infection related products.
0.00%
20.00%
40.00%
60.00%
glaucoma allergy infection otic
Pharmaceutical sales by category In
percentage
Pharmaceutical sales by
category In percentage
8/2/2019 3rd Sem Report
39/44
Sandoz pharmaceuticals
Introduction
Sandoz is a part of a Novartis group,it is the world leader in the field of generic
pharmaceutical sector offer the wide area of high quality and affordable products which
are protecte patent for a longer time..
Sandoz is the number one firm to receive a US approval in the market a more
affordable generic side of the top hospital based pills in the USA.
Sandoz have the portfolio of arounds 1000 compounds and sells its products in more
than 130 country
Sendoz is one of the 1st
company to launch generic enopxaparin sodium in US. deliveron there steategy in the market with key the of product, and underscore our leadership
in different product jeff George global head of Sandoz. They are welcome the fda
decision for approve there enoxaparin application, and company also by providing high-
quqlity and more affordable version.
Sandoz has global presence. Sandoz employs over 24,000 people in about 130countries, and has 12 development centers and a worldwide network of more than 30production sites. This is widespread presence is fundamental to our global leadershipposition in developing and producing high-quality generics and differentiated products,including biosimilars.
History:
sendoz is more prevail more than 120 years, during this time it has transforme itself
from a small chemical company to the worlds 2nd largest producer firm of super
standard pharmaceuticals and worldwide leader in biosimilars as well as different
products. Through our long and illustrious history, we have been led by committed and
imaginative individuals who has forever aspire to be more one move ahead and who
have delivered success from end to end high-quality product and service.
8/2/2019 3rd Sem Report
40/44
The Early Years 1886-1939
1964- The first research center which was outside switzeland was established at EastHanover, NJ ,in US follow by the Sandoz research institute in the year 1970 and theSandoz institute for check-up investigate in London, UK 1985.
1967- company merger with the wander Ltd and diversified in that the dileteticsbusiness acquiring Delmark in 1972 was a in 1982 and Gerber Babyfood in 1994.
1975- The seeds market was entered through the the acquisition between AmericanRogers seeds company with Northrup ruler in 1976 the Dutch group in 1980 and theSwedish company in 1989
1977- The anti-allergic drug Zaditen was introduced
1981- Sandoz institute Medical investigate is founded in the location of Universitycollege, London and united kingdom
1982- The immunosuppressant sandimmum is introduced followed by Neoral in 1994.
Vision
Sendoz will be the main provider of high quality, affordable medicines helping securelong-term access for healthcare for people around the world.Sendoz will go beyond traditional generic products and bring innovative technology anddelivery systems to the market, making a world of difference in generic.Sendoz will lead theire industry, out performing the market.Sendoz will bring the care and passion to their employees has for its work to itscustomers, patient and communities.
Scope:
- Gain insight into Sandoz's strategic outlook across the next six years- its sales forecasts basis on product, psychoanalysis area, lifecycle stage, naturalfeatures, bit type and source- Strategic insight into the prospects for Sandoz over its next six years.
8/2/2019 3rd Sem Report
41/44
Market Information
Sandoz hed been sales in 2009 with worth US$7,495 millions, demonstrating a slight
drop of 0.8% over 2008, when sales reached US$7,556 million. The year saw Sandoz'
US trade return to expansion, getting better by 4.6% over 2008 to US$1,844 million.
However, sales in Europe fell by 4.8% to US$4272 million.
In Sept 2009, company is going with the Novartis, complete its acquirement of the
branch of education generic injectables industry of Ebewe Pharma.
Key company figures for 2011
USD 9.5 billion in sales (+7 % in CC*, +10 % in USD)USD 1.9 billion in core operating income (+11 % in CC, +10 % in USD)
USD 1.4 billion in operating income (+10 % in CC, + 8 % in USD)More than 24 000 employees in about 130 countriesApproximately 1 000 molecules worldwide12 global development centersMore than 30 manufacturing sites globallySandoz medicines available to over 90 % of the worlds population
0
1
2
3
4
5
6
7
8
9
10
2005 2008 2011
8/2/2019 3rd Sem Report
42/44
8/2/2019 3rd Sem Report
43/44
Summary
Nycomed:
Nycomed Is 28th Largest Pharmaceutical Company In all over world.
In more than 70 Countries, where nycomed subsidiaries are present.
Nycomeds biggest-selling product, pantoprazole (acid-related Gastroenterology
disorders)
Contribution of turnover of NYCOMED by region is more in European countries
i.e.43%.while Asian-Pacific And African Countries Countributes 8% Turnover.
Novartis:
The pharmaceutical industry is a key sector of the Swiss economy and a major
employer.
The sector is directly and indirectly responsible for added value amounting to 5.7
percent of the nominal gross domestic product.
Novartis is the only healthcare company with leading positions in
pharmaceuticals, eye care, generics, vaccines and diagnostics, over-the-counter
medicines and animal health.
Novartis is one of Switzerlands largest exporters, accounting for 14.3 % of total
national net exports.
Alliance Boots:
Alliance Boots has two core business activities pharmacy health and beauty
retailing, and pharmaceutical wholesaling and distribution.
8/2/2019 3rd Sem Report
44/44
Alliance Boots is also the largest pharmaceutical wholesaler in the UK by its
Alliance Healthcare (Distribution) Ltd business.
ALCON PHARMACEUTICAL:
Alcon offers the widest spectrum of eye care products in surgical,
Pharmaceutical and Vision Care across 180 markets and runs operations in 75
countries.
Alcon is the market leader in ophthalmic surgical products, providing the most
comprehensive surgical portfolio in the world.
Alcon is now one of the largest manufacturers of contact lenses and lens care
products.
Sandoz:
Sandozis a worldwide leader in generics.
This strategy of concentration on specialties is the Swiss chemical and
pharmaceutical industry's key to success. With their high-grade specialized products
Swiss companies have established a world-wide presence, and often a market
leadership.
Recommended